LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.